BTCC / BTCC Square / Global Cryptocurrency /
OSR Holdings Jumps 27% on Vaximm’s $815M Licensing Deal with BCM Europe

OSR Holdings Jumps 27% on Vaximm’s $815M Licensing Deal with BCM Europe

Published:
2025-11-21 20:57:02
19
3
BTCCSquare news:

OSR Holdings, Inc. (OSRH) surged 27% intraday after its subsidiary Vaximm AG announced a strategic licensing agreement with BCM Europe AG for cancer immunotherapy drug VXM01. The non-binding term sheet outlines a potential $20M upfront payment and $815M in milestones, triggering investor Optimism about OSRH's biotech portfolio.

Market reaction was immediate, with OSRH stock outperforming broader indices. The six-month exclusivity window allows due diligence for a definitive agreement, positioning Vaximm for global commercialization. Biotech analysts note the deal validates OSRH's investment thesis in novel immunotherapies.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.